Regeneron monoclonal antibodies (anti-Spike SARS-CoV-2 MAbs)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Regeneron monoclonal antibodies (anti-Spike SARS-CoV-2 MAbs), covering 2023-05-15 to 2023-05-15. Get the full timeline:
Most recent: Clinical Trial Update: COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay [Phase 3]